Académique Documents
Professionnel Documents
Culture Documents
Summary
Background The xed-dose combination of any two antihypertensive drugs from dierent drug classes is typically
more eective in reducing blood pressure than a dose increase of component monotherapy. We assessed the ecacy
and safety of a xed-dose combination of a vasodilating blocker (nebivolol) and an angiotensin II receptor blocker
(valsartan) in adults with hypertension.
Methods We did an 8-week, phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group trial at
401 US sites. Participants (age 18 years) with hypertension but with blood pressure less than 180/110 mm Hg were
randomly assigned (2:2:2:2:2:2:2:1) by a 24-h interactive web response system in blocks of 15 to 4 weeks of double-blind
treatment with nebivolol and valsartan xed-dose combination (5 and 80 mg/day, 5 and 160 mg/day, or 10 and
160 mg/day), nebivolol (5 mg/day or 20 mg/day), valsartan (80 mg/day or 160 mg/day), or placebo. Doses were doubled
in weeks 58; results are reported according to the nal dose. Participants and research sta were masked to treatment
allocation. The primary and key secondary endpoints were changes from baseline to week 8 in diastolic and systolic
blood pressure, respectively. The primary statistical comparison was between the highest xed-dose combination dose
and the highest monotherapy doses; lower doses were then compared if this comparison was positive (Hochberg
method for multiple testing). Ecacy analyses were by intention to treat. Safety assessments included monitoring of
adverse events. Continuous ecacy parameters were analysed using an ANCOVA model; binary outcomes were
analysed using a logistic regression model. This study is registered with ClinicalTrials.gov, NCT01508026.
Findings Between Jan 6, 2012, and March 15, 2013, 4161 patients were randomly assigned (277 to placebo and 554555
to each active comparator group), 4118 of whom were included in the primary analysis. At week 8, the xed-dose
combination 20 and 320 mg/day group had signicantly greater reductions in diastolic blood pressure from baseline
than both nebivolol 40 mg/day (least-squares mean dierence 12 mm Hg, 95% CI 23 to 01; p=0030) and
valsartan 320 mg/day (44 mm Hg, 54 to 33; p<00001); all other comparisons were also signicant, favouring
the xed-dose combinations (all p<00001). All systolic blood pressure comparisons were also signicant (all p<001).
At least one treatment-emergent adverse event was experienced by 3036% of participants in each group.
Interpretation Nebivolol and valsartan xed-dose combination is an eective and well-tolerated treatment option for
patients with hypertension.
Introduction
The combination of two antihypertensive drugs from
dierent classes is likely to cause a greater reduction in
blood pressure than would an increase in the monotherapy
dose.1 For patients who need more than one drug to
achieve blood pressure control, treatment should
commence with two drugs, either as separate entities or
as a xed-dose combination.2,3
The use of antihypertensive xed-dose combinations
compared with higher doses of the monotherapy
components has been associated with improved blood
pressure control,14 lower rates of adverse events, and
improved drug adherence.36 Moreover, xed-dose
combinations make the assessment of pharmacological
compatibility of the combined drugs easier for
prescribers, resulting in more predictable treatment
results compared with free combinations.
Nebivolol and valsartan are two antihypertensive drugs
with proven safety and tolerability.7,8 The mechanism of
www.thelancet.com Vol 383 May 31, 2014
Methods
Study design and participants
We did a phase 3, multicentre, randomised, double-blind,
placebo-controlled, parallel-group trial at 401 US sites. The
central laboratories were ACM Global Central Laboratory
(Rochester, NY, USA; clinical laboratory determinations),
Quest Diagnostics (San Juan Capistrano, CA, USA;
1889
Articles
Procedures
Blood pressure and pulse rate were measured using an
automatic monitoring device (Omron HEM-705CP,
Lake Forest, IL, USA). After a 5-min rest period, four
separate sitting blood pressure measurements were
taken at drug trough (the period at the end of the dosing
interval) with a 25 min interval between measurements.
The mean of the last three values constituted the blood
pressure value for the visit. Seated pulse rate was the
mean obtained at the same time the last three seated
blood pressure measurements were taken. A 24-h
ABPM was recorded from substudy participants at
week 0 and week 8 using a Spacelabs 90207 (Snoqualmie,
WA, USA) oscillometric device that was automatically
set to measure and record blood pressure. Blood
samples for assessment of biomarker levels were also
collected from substudy participants.
Outcomes
The primary ecacy endpoint was the change in trough
seated diastolic blood pressure from baseline to week 8
and the key secondary ecacy endpoint was change in
seated systolic blood pressure from baseline to week 8.
Other secondary ecacy parameters were changes from
www.thelancet.com Vol 383 May 31, 2014
Articles
Statistical analysis
Assuming a diastolic blood pressure mean treatment
dierence of 2 mm Hg (SD 8) between the xed-dose
combination 20 and 320 mg/day and the nebivolol
40 mg/day groups, and between the xed-dose
combination 20 and 320 mg/day and the valsartan
320 mg/day groups and on the basis of pairwise t test
comparisons, 500 participants would need to be
randomly assigned to each active-treatment group and
250 to placebo (total 3750 participants) to provide 95%
power to detect a 2 mm Hg (SD 8) treatment dierence
or greater at the two-tailed 5% signicance level. If the
study was positive, the study size would provide a further
90% power to detect a mean dierence of 2 mm Hg
(SD 8) between xed-dose combinations 10 and
160 mg/day and 10 and 320 mg/day and the
corresponding monotherapy groups, with multiplicity
adjustment using the Hochberg procedure,15 at the twotailed 5% signicance level.
www.thelancet.com Vol 383 May 31, 2014
Articles
277 assigned
to placebo
555 assigned
to 5 and
80 mg/day
FDC weeks
14 and 10
and
160 mg/day
weeks 58
33 discontinued
10 adverse
events
9 insucient
response
5 lost to
follow-up
2 protocol
violation
5 withdrew
consent
2 other
555 assigned
to 5 and
160 mg/day
FDC weeks
14 and 10
and
320 mg/day
weeks 58
65 discontinued
15 adverse
events
6 insucient
response
5 lost to
follow-up
12 protocol
violation
22 withdrew
consent
5 other
554 assigned
to 10 and
160 mg/day
FDC weeks
14 and 20
and
320 mg/day
weeks 58
59 discontinued
9 adverse
events
5 insucient
response
13 lost to
follow-up
4 protocol
violation
20 withdrew
consent
8 other
555 assigned
to 5 mg/day
nebivolol
weeks
14 and
10 mg/day
weeks 58
48 discontinued
9 adverse
events
3 insucient
response
9 lost to
follow-up
6 protocol
violation
12 withdrew
consent
9 other
555 assigned
to 20 mg/day
nebivolol
weeks
14 and
40 mg/day
weeks 58
50 discontinued
12 adverse
events
6 insucient
response
9 lost to
follow-up
4 protocol
violation
12 withdrew
consent
7 other
555 assigned
to 80 mg/day
valsartan
weeks
14 and
160 mg/day
weeks 58
76 discontinued
22 adverse
events
1 insucient
response
11 lost to
follow-up
11 protocol
violation
18 withdrew
consent
13 other
555 assigned to
160 mg/day
valsartan
weeks
14 and
320 mg/day
weeks 58
57 discontinued
10 adverse
events
12 insucient
response
9 lost to
follow-up
6 protocol
violation
13 withdrew
consent
7 other
58 discontinued
10 adverse
events
7 insucient
response
9 lost to
follow-up
11 protocol
violation
17 withdrew
consent
4 other
244 completed
the study
490 completed
the study
496 completed
the study
506 completed
the study
505 completed
the study
479 completed
the study
498 completed
the study
497 completed
the study
277 included in
ITT analysis
549 included in
ITT analysis*
548 included in
ITT analysis*
550 included in
ITT analysis*
552 included in
ITT analysis*
547 included in
ITT analysis*
548 included in
ITT analysis*
547 included in
ITT analysis*
Results
Between Jan 6, 2012 (rst participant, rst visit), and
March 15, 2013 (last participant, last visit), 4161 participants were randomly assigned to receive double-blind
treatment, 4118 of whom were included in the intentionto-treat population (gure 1). Mean demographic and
clinical characteristics (table) and study completion rates
(gure 1) were comparable between treatment groups.
Consent withdrawal was the most frequent reason for
discontinuation in all active-treatment groups, with the
exception of nebivolol 40 mg/day (adverse events) and
nebivolol 10 mg/day (consent withdrawal; adverse events;
gure 1). Adherence at each visit was at least 99% for
every group.
The mean dierence in diastolic blood pressure
between baseline and week 8 ranged from 148 mm Hg
(SD 92) for the 10 and 160 mg/day xed-dose
combination to 157 mm Hg (96) for the 20 and
320 mg/day xed-dose combination; from 127 mm Hg
(90) for nebivolol 10 mg/day to 144 mm Hg (94) for
nebivolol 40 mg/day; and from 108 mm Hg (96) for
valsartan 160 mg/day to 112 mm Hg (93) for valsartan
320 mg/day (gure 2A). At week 8, the xed-dose
1892
Articles
Placebo
(n=277)
Age (years)
511 (104)
10 and
320 mg/day
(n=555)
20 and
320 mg/day
(n=554)
509 (101)
516 (98)
508 (97)
10 mg/day
(n=555)
160 mg/day
(n=555)
320 mg/day
(n=554)
517 (99)
511 (107)
517 (102)
40 mg/day
(n=554)
515 (108)
Sex
Men
148 (53%)
300 (54%)
315 (57%)
313 (56%)
307 (55%)
297 (54%)
333 (60%)
295 (53%)
Women
129 (47%)
255 (46%)
240 (43%)
241 (44%)
248 (45%)
257 (46%)
222 (40%)
259 (47%)
White
231 (83%)
464 (84%)
475 (86%)
474 (86%)
452 (81%)
471 (85%)
481 (87%)
475 (86%)
Black
30 (11%)
56 (10%)
56 (10%)
52 (9%)
69 (12%)
54 (10%)
43 (8%)
51 (9%)
Other
16 (6%)
35 (6%)
24 (4%)
28 (5%)
34 (6%)
29 (5%)
31 (6%)
28 (5%)
Race
Ethnic origin
Hispanic
113 (41%)
252 (45%)
239 (43%)
231 (42%)
206 (37%)
220 (40%)
207 (37%)
216 (39%)
Non-Hispanic
164 (59%)
303 (55%)
316 (57%)
323 (58%)
349 (63%)
334 (60%)
348 (63%)
338 (61%)
Weight (kg)
936 (206)
911 (204)
922 (200)
922 (208)
924 (212)
913 (212)
923 (208)
326 (60)
319 (63)
320 (60)
320 (65)
321 (63)
320 (63)
318 (60)
921 (208)
320 (60)
Type 2 diabetes
40 (14%)
81 (15%)
88 (16%)
89 (16%)
82 (15%)
86 (16%)
84 (15%)
88 (16%)
522 (94%)
535 (97%)
264 (95%)
532 (96%)
524 (94%)
533 (96%)
532 (96%)
526 (95%)
212/264 (80%)
429/532 (81%)
408/533 (77%)
432/532 (81%)
1554 (112)
1546 (118)
1554 (111)
1546 (115)
1551 (118)
1551 (116)
1558 (121)
1551 (117)
998 (35)
996 (35)
996 (35)
999 (37)
999 (35)
998 (36)
998 (38)
997 (36)
780 (107)
778 (110)
773 (107)
782 (108)
770 (107)
776 (108)
775 (107)
52 (19%)
108 (19%)
109 (20%)
110 (20%)
106 (19%)
109 (20%)
104 (19%)
771 (114)
107 (19%)
Data are mean (SD) or number (%). Some percentages do not total 100 because of rounding. ABPM=ambulatory blood pressure monitoring. DBP=diastolic blood pressure. SBP=systolic blood pressure.
*Percentages are relative to the numbers of patients previously diagnosed with hypertension. Intention-to-treat population.
Articles
0
998
996
998
999
996
997
998
999
1554
1546
1558
1551
1554
1551
1546
4
6
8
10
12
14
16
p<00001
18
p<00001 p<00001
p<00001
p=0030
p<00001
p<00001
p<00001
bo
80
m 0a
g/ nd
da
y
16 Va
0 m lsa
g/ rtan
da
y
N
10 eb
m ivo
g/ lo
d l
FD ay
32 C
0 m 10
g/ and
da
y
V
32 a
0 m lsa
g/ rtan
da
y
40 Neb
i
m vo
g/ lo
da l
FD y
32 C
0 m 20
g/ and
da
y
C1
ce
p=0001
p=00005
Week 4
Placebo
Valsartan 80 mg/day
Valsartan 160 mg/day
Nebivolol 5 mg/day
Nebivolol 20 mg/day
FDC 5 and 160 mg/day
FDC 5 and 80 mg/day
FDC 10 and 160 mg/day
0
2
4
6
Week 8
Placebo
Valsartan 160 mg/day
Valsartan 320 mg/day
Nebivolol 10 mg/day
Nebivolol 40 mg/day
FDC 10 and 160 mg/day
FDC 10 and 320 mg/day
FDC 20 and 320 mg/day
8
10
12
14
16
18
p=0001
FD
Pla
bo
ce
FD
Pla
80 C 1
m 0a
g/ nd
da
y
16 Va
0 m lsa
g/ rtan
da
N y
10 eb
m ivo
g/ lo
da l
y
FD
32 C
0 m 10
g/ and
da
y
32 Va
0 m lsa
g/ rtan
da
y
40 Neb
m ivo
g/ lo
d l
F ay
32 DC
0 m 20
g/ and
da
y
p<00001
1551
2
0
2
4
6
FDC 5 and 80 mg/day vs nebivolol 5, p=00001
FDC 5 and 80 mg/day vs valsartan 80, p=00007
FDC 5 and 160 mg/day vs nebivolol 5, p<00001
FDC 5 and 160 mg/day vs valsartan 160, p=011
8
10
12
14
16
18
0
4
Week
Figure 2: Changes in trough seated diastolic and systolic blood pressure from baseline to week 8 and visit by visit
Analyses were by intention to treat, last observation carried forward. All active-treatment groups were signicantly dierent from placebo at weeks 4 and 8 (p<0001
for all). Error bars are SEM. (A and B) Numbers in bars are mean values at baseline. FDC=xed-dose combination.
1894
Articles
0
858
873
866
886
1373
4
1422
1408
1418
6
10
8
10
15
12
14
20
p<00001
Placebo
(n=52)
FDC
20 and 320
mg/day
(n=110)
Nebivolol
40 mg/day
(n=107)
Valsartan
320 mg/day
(n=105)
p<00001
p=00002
p<00001
50
p=0003
233
549
40
242
218 550
547
227
548
180
171
548
552
30
p=00005
Placebo
FDC 5 and 80 mg/day
Valsartan 80 mg/day
Nebivolol 5 mg/day
FDC 5 and 160 mg/day
Valsartan 160 mg/day
Nebivolol 20 mg/day
FDC 10 and 160 mg/day
FDC
20 and 320
mg/day
(n=110)
Nebivolol
40 mg/day
(n=107)
p=0001
p<00001 p<00001
p=00001
268
549
p=0023
285
550
256
548
213
200 552
548
174
547
20
10
Placebo
(n=52)
60
p=0003
247
547
Valsartan
320 mg/day
(n=105)
Placebo
FDC 10 and 160 mg/day
Valsartan 160 mg/day
Nebivolol 10 mg/day
FDC 10 and 320 mg/day
Valsartan 320 mg/day
Nebivolol 40 mg/day
FDC 20 and 320 mg/day
195
547
58
277
47
277
0
Week 4
Week 8
Figure 3: Changes in trough seated diastolic and systolic blood pressure in the ambulatory blood pressure monitoring substudy and blood pressure control
rates between baseline and week 8
Analyses were by intention to treat, last observation carried forward. (A and B) Numbers in bars are mean values at baseline. (C) Blood pressure control is dened as
blood pressure <130/80 mm Hg for individuals with type 2 diabetes or <140/90 mm Hg for those without. Numbers in bars are ratios of responders versus participants
in a given group. FDC=xed-dose combination.
Articles
0
780
778
775
773
770
771
776
782
2
4
6
8
10
12
14
p<00001
p<00001
p<00001
556
550
560
552
558
554
554
547
Discussion
p=0021
p=0052
p=00053
p=0053
Placebo
FDC
Valsartan Nebivolol
10 and 160 160 mg/day 10 mg/day
mg/day
FDC
Valsartan
Nebivolol
FDC
10 and 320 320 mg/day 40 mg/day 20 and 320
mg/day
mg/day
Figure 4: Mean changes in pulse rate and pulse pressure between baseline and week 8
Analyses were by intention to treat, last observation carried forward. Numbers in bars show mean values at
baseline. FDC=xed-dose combination.
Articles
Placebo
Men
310
148
Women
240
129
Sex
BMI
30 kg/m2
310
177
<30 kg/m2
240
100
Ethnic origin
Hispanic
228
113
Non-Hispanic
322
164
Race
52
30
498
247
<65 years
509
250
65 years
41
27
Black
Non-black
Age (years)
Diabetes
Yes
89
40
No
461
237
239
121
Median
311
156
16 14 12 10 8 6 4 2 0 2 4
Systolic blood pressure (mm Hg),
LSMD (95% CI)
16 14 12 10 8 6 4 2 0 2 4
Diastolic blood pressure (mm Hg),
LSMD (95% CI)
Figure 5: Antihypertensive eects of xed-dose combination 20 and 320 mg/day (placebo-subtracted values) by subgroup
Analyses were by intention to treat, last observation carried forward. BMI=body-mass index. FDC=xed-dose combination. LSMD=least-squares mean dierence.
1897
Articles
1898
9
10
11
12
13
14
15
16
17
18
19
20
21
Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Singlepillvsfree-equivalent combination therapies for hypertension:
ameta-analysis of health care costs and adherence.
J Clin Hypertens (Greenwich) 2011; 13: 898909.
Imaizumi S, Miura S, Yahiro E, Uehara Y, Komuro I, Saku K.
Class- and molecule-specic dierential eects of angiotensin II
type 1 receptor blockers. Curr Pharm Des 2013; 19: 300208.
Weiss RJ, Saunders E, Greathouse M. Ecacy and tolerability
ofnebivolol in stage III hypertension: a pooled analysis of data
from three randomized, placebo-controlled monotherapy trials.
Clin Ther 2011; 33: 115061.
Gao Y, Vanhoutte PM. Nebivolol: an endothelium-friendly selective
1-adrenoceptor blocker. J Cardiovasc Pharmacol 2012; 59: 1621.
Vanhoutte PM, Gao Y. Beta blockers, nitric oxide, and
cardiovascular disease. Curr Opin Pharmacol 2013; 13: 26573.
Hussein O, Shneider J, Rosenblat M, Aviram M. Valsartan therapy
has additive anti-oxidative eect to that of uvastatin therapy
against low-density lipoprotein oxidation: studies in
hypercholesterolemic and hypertensive patients.
J Cardiovasc Pharmacol 2002; 40: 2834.
Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S. Angiotensin II
type 1 receptor blockers reduce urinary oxidative stress markers in
hypertensive diabetic nephropathy. Hypertension 2006; 47: 699705.
ICH Expert Working Group. International Conference on
Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use. Principles for Clinical Evaluation
of New Antihypertensive Drugs. 2000. http://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm073147.pdf (accessed Feb 1, 2014).
US Food and Drug Administration. Ttile 21. Code of Federal
Regulators. Section 310.545. Subchapter D: Drugs for Human Use,
Part 300, Subpart B-Combination Drugs. Washington, DC:
USDepartment of Health and Human Services, 2013.
Hochberg Y. A sharper Bonferroni procedure for multiple tests
ofsignicance. Biometrika 1988; 75: 80002.
Gradman AH, Basile JN, Carter BL, et al. Combination therapy
inhypertension. J Am Soc Hypertens 2010; 4: 9098.
Makani H, Bangalore S, Supariwala A, Romero J, Argulian E,
Messerli FH. Antihypertensive ecacy of angiotensin receptor
blockers as monotherapy as evaluated by ambulatory blood pressure
monitoring: a meta-analysis. Eur Heart J 2013; published online
Aug 21. DOI:10.1093/eurheartj/eht333.
Markham A, Goa KL. Valsartan. A review of its pharmacology and
therapeutic use in essential hypertension. Drugs 1997; 54: 299311.
Ambrosioni E, Borghi C. Tolerability of nebivolol in head-to-head
clinical trials versus other cardioselective -blockers in the
treatment of hypertension. High Blood Press Cardiovasc Prev 2005;
12: 2735.
Kountz DS. Are tolerability concerns a class eect of beta-blockers
in treating patients with hypertension? Postgrad Med 2009;
121: 1424.
Weir MR, Levy D, Crikelair N, Rocha R, Meng X, Glazer R.
Timetoachieve blood-pressure goal: inuence of dose of valsartan
monotherapy and valsartan and hydrochlorothiazide combination
therapy. Am J Hypertens 2007; 20: 80715.